rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cocrystal Pharma, Inc.

COCP · Nasdaq

Health CareBiotechnologyNot moving yet

COCP stood above a rising 150-day average in 10 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 10.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$495K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
25 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$171KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months10
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Phillip Md Et Al FrostDirector, 10% ownerbought10,000at $0.98165 Aug 2026filed 6 Aug 2026
Phillip Md Et Al FrostDirector, 10% ownerbought75,000at $0.94123 Aug 2026filed 5 Aug 2026
Phillip Md Et Al FrostDirector, 10% ownerbought20,000at $0.997624 Feb 2026filed 25 Feb 2026
Phillip Md Et Al FrostDirector, 10% ownerbought50,000at $0.94566 Feb 2026filed 9 Feb 2026
Phillip Md Et Al FrostDirector, 10% ownerbought50,000at $0.945531 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders25+1 on the quarter
New · exited6 · 4
Reported value$1.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026358,228$376K+118,257+49.3%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026179,628$189K+55,700+44.9%
TWO SIGMA INVESTMENTS, LPnew · filed 14 Aug 2026175,379$184K+175,379
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202676,208$80K-14,023−15.5%
BlackRock, Inc.unchanged · filed 7 Aug 202673,746$77K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202645,118$47K+45,118
NEUBERGER BERMAN GROUP LLCunchanged · filed 13 Aug 202631,886$33K00.0%
XTX Topco Ltdreduced · filed 14 Aug 202629,342$31K-6,689−18.6%
JANE STREET GROUP, LLCadded · filed 14 Aug 202625,761$27K+13,050+102.7%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202624,016$25K00.0%
31 Mar 2023 – 30 Jun 2026
131925Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Phillip Et Al Frost Company insiderDirector, 10% owner · last 5 Aug 202612 · 0
James Sapirstein Company insiderChief Executive Officer · last 3 Jun 20260 · 0
Anthony J. Japour Company insiderDirector · last 9 Jan 20260 · 0
Fred Hassan Company insiderDirector · last 9 Jan 20260 · 0
James Joseph Martin Company insiderCo-CEO and CFO · last 9 Jan 20260 · 0
Richard C. Pfenniger Jr. Company insiderDirector · last 9 Jan 20261 · 0
Roger D. Kornberg Company insiderDirector · last 9 Jan 20260 · 0
Sam Lee Company insiderPresident and Co-CEO · last 9 Jan 20260 · 1
Steven D. Rubin Company insiderDirector · last 9 Jan 20263 · 0
Raymond F. Schinazi Company insider10% owner · last 4 May 20216 · 1
Gary Wilcox Company insiderChief Executive Officer · last 22 Jun 20203 · 0
David S. Block Company insiderDirector · last 21 Sep 20183 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-120%
Share count trendFY 2025 · to 24 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.0M
Free cash flowFY 2025 · to 31 Dec 2025−$8.2M

Analyst forecasts

No analyst forecasts yet.